Thymosin Alpha-1: The Thymic Peptide With Four Decades of Clinical Evidence and a Divided Global Regulatory Map

Key takeaways

• Thymosin alpha-1 (Tα1) is a 28-amino-acid thymic peptide approved as a prescription medicine (Zadaxin/thymalfasin) in more than 35 countries, giving it the deepest clinical evidence base of any compound in the BSR research catalogue.
• It is not FDA-approved in the United States and holds no MHRA marketing authorisation in the United Kingdom; UK supply is confined to clearly labelled research-use-only material with appropriate documentation.
• Tα1's US compounding trajectory diverged from the seven peptides reviewed at the 23–24 July 2026 PCAC meeting: it was removed from the FDA's Category 2 restricted list in a separate earlier process, and no formal 503A rulemaking has been completed.
• The most robust human evidence covers chronic hepatitis B, with controlled trials spanning three decades reporting HBeAg seroconversion rates of 25–40% on subcutaneous Tα1 monotherapy.
• Active 2025–2026 research is investigating Tα1 in sepsis immune-reconstitution and as an oncology adjuvant, though results remain heterogeneous.

What is thymosin alpha-1?

Thymosin alpha-1 (Tα1; thymalfasin; CAS 62304-98-7) is a 28-amino-acid peptide that represents the N-terminal fragment of the larger thymic protein prothymosin alpha. It was first isolated from bovine thymus tissue and characterised by Dr Allan Goldstein in the 1970s. The synthetic version used in clinical and research settings is chemically identical to the endogenous peptide.

Tα1 acts as an immunomodulator rather than a simple immune stimulant: it recalibrates T-cell maturation and Th1/Th2 balance via toll-like receptor 9 (TLR9) signalling on dendritic cells. The mechanistic pathway proceeds through MyD88 to IRF7-dependent activation of indoleamine 2,3-dioxygenase, with downstream restoration of T-regulatory and effector T-cell balance. Tα1 also activates TLR-2 on dendritic cells, driving maturation and subsequent T-cell differentiation into CD4+ and CD8+ effector populations. This dual receptor engagement is why clinical research has focused on conditions characterised by immune exhaustion or insufficient adaptive response rather than straightforward infection.

Clinical evidence: what the trials show

Chronic hepatitis B — the foundational dataset

Tα1 is approved as a medicine in approximately 30–35 countries — including Italy, China, and much of South-East Asia — for chronic hepatitis B and as a chemotherapy adjuvant. The approved-medicine brand, Zadaxin, has been marketed since the 1990s.

Multiple controlled trials between 1995 and 2010 demonstrated that Tα1 monotherapy at 1.6 mg subcutaneous twice weekly for 24–26 weeks achieves HBeAg seroconversion rates of roughly 25–40%, comparable to interferon-alpha but with a substantially better tolerability profile — without the flu-like syndrome and haematological toxicity associated with interferon. A meta-analysis covering 1,316 patients across 14 trials found Tα1 combined with interferon-alpha produced higher sustained virological response rates in hepatitis B than interferon monotherapy.

The pivotal 1998 randomised controlled trial in 98 hepatitis B patients reported complete virological response in 40.6% on thymosin alpha-1 versus 9.4% in untreated controls, establishing the foundational efficacy signal that underpinned international regulatory approvals.

A separate evidence stream has evaluated Tα1 in chronic hepatitis C. Active 2026 clinical trials combining Tα1 with pegylated interferon are measuring whether dual immune stimulation increases HBsAg clearance rates, addressing a persistent clinical problem: functional cure — defined as HBsAg loss with sustained undetectable HBV DNA — occurs in fewer than 10% of patients on standard nucleoside analogue therapy.

Sepsis and critical illness

The sepsis application represents an area of active, and contested, research. A 2025 systematic review and meta-analysis published in Frontiers in Cellular and Infection Microbiology evaluated thymosin α1 for sepsis across randomised controlled trials, with thymosin α1 showing promise as an immunomodulator, though the authors noted heterogeneity across study populations.

The largest prospective trial — the TESTS trial, which enrolled 1,106 adults with sepsis at 22 Chinese centres — reported a 28-day all-cause mortality hazard ratio of 0.94 (95% CI 0.76–1.16, p=0.54), which was not statistically significant. A 2025 meta-analysis of 11 randomised controlled trials reported a pooled odds ratio of 0.73, but the authors flagged significant heterogeneity. Sepsis therefore remains an active research question rather than a settled Tα1 application, and UK procurement teams should treat this indication cautiously when evaluating research justifications.

Severe acute pancreatitis

A 2025 systematic review and meta-analysis published in Frontiers in Immunology evaluated Tα1 specifically in severe acute pancreatitis (SAP). Five randomised controlled trials comprising 706 patients with SAP were included, examining whether Tα1's immune-regulatory properties could alleviate the inflammatory and infectious complications that exacerbate this condition. The rationale aligns mechanistically with Tα1's established profile: immune and inflammatory disorders are central to the pathophysiology that exacerbates SAP and subsequent infection.

Oncology adjuvant

Thymosin alpha-1 is approved internationally as an adjuvant to chemotherapy, reflecting evidence that it partially counteracts chemotherapy-induced immune suppression. Ongoing 2026 oncology trials are structured around combination protocols rather than monotherapy endpoints, given Tα1's mechanism acts on adaptive immune priming rather than direct tumour cytotoxicity. Interim data from at least one active Phase 2/3 combination trial measuring progression-free survival by RECIST 1.1 is expected in Q3 2027.

Regulatory position: a globally split picture

International approvals

Tα1 (Zadaxin/thymalfasin) is approved as a prescription medicine in more than 35 countries for chronic hepatitis B, chronic hepatitis C, and cancer adjuvant therapy. China and Italy hold the two largest bodies of approved-product clinical experience. The original and largest clinical research dataset originates from these two jurisdictions, because Tα1 has been simultaneously available as a marketed medicine and as a research probe for two decades there.

United States

Tα1 is not FDA-approved for any indication in the United States. The FDA has granted orphan drug status for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly, and hepatocellular carcinoma, but orphan designation is not an approval and does not permit general prescribing.

Tα1's US compounding trajectory is distinct from the seven peptides reviewed at the July 2026 PCAC meeting. On 27 February 2026, HHS Secretary Robert F. Kennedy Jr. announced that Tα1 was among the 14 peptides being reclassified away from Category 2, which had restricted compounding since late 2023. However, no formal rulemaking has been published following that announcement, meaning the compound's 503A compounding status has not been formally resolved. Until the FDA publishes a final rule, the prior research-only landscape applies.

United Kingdom

No MHRA marketing authorisation for thymosin alpha-1 exists as of 2026. Tα1 is not approved by the MHRA for human therapeutic use in standard clinical practice; however, it is not explicitly scheduled as a controlled substance under the Misuse of Drugs Act.

For UK research laboratories, this means Tα1 may be sourced and held for legitimate in vitro or preclinical research purposes under appropriate institutional governance. Supply for research purposes requires appropriate Certificates of Analysis verifying identity, purity, and quality, with material explicitly labelled for research use only. Any clinical or human-administration context would require a clinical trial authorisation from the MHRA or another recognised regulatory pathway. The European picture mirrors this: individual EU member states may have their own authorisation pathways, but there is no EU-wide marketing authorisation separate from national approvals.

Procurement considerations for UK research labs

Tα1's evidence profile creates several practical considerations for research-procurement teams:

1. Purity standards matter for mechanistic reproducibility. The peptide's TLR activation cascade is sensitive to sequence accuracy and formulation; research-grade material synthesised under GMP conditions with ≥98% purity verified by HPLC is the accepted standard in published trial protocols. Certificate of Analysis review should confirm HPLC purity, mass spectrometry identity confirmation, and sterility testing where injectable formulations are intended for in vivo animal work.

2. Regulatory asymmetry creates sourcing complexity. Because Zadaxin is a licensed pharmaceutical product in some jurisdictions, procurement teams should verify that research-grade Tα1 is sourced through documented supply chains with no ambiguity about its research-only designation. Material marketed as pharmaceutical-grade Zadaxin from unlicensed online vendors should be treated as a quality and regulatory risk.

3. Evidence base is real but indication-specific. Thymosin alpha-1 has the strongest clinical evidence base of any immune peptide in the research catalogue; however, the hepatitis B dataset does not automatically support extrapolation to sepsis or oncology endpoints without additional institutional review. Research protocols should be anchored to the specific mechanistic hypothesis being tested.

Outlook

Tα1 sits in an unusual position for a research peptide: it is simultaneously a licensed pharmaceutical product in three dozen markets and a research-use-only compound in the UK and US. That duality means the evidence base is unusually robust — decades of randomised trials rather than preclinical rodent models — but that regulatory access in the UK and US is no more straightforward than for less-evidenced compounds. The compound's US reclassification trajectory, while directionally positive, has not yet resulted in formal compounding authorisation, and the UK position is unchanged. For procurement purposes, Tα1 remains a research material requiring the same documentation rigour as any other peptide in the catalogue, notwithstanding its international approved-medicine status.